Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma

Chinese Medical Journal

Volumn 117, Issue 10, 2004, Pages 1547-1551

  Liu, En Ling ^a   Mi, Ruo Ran ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Drug therapy; Embolization; Neoadjuvant therapy; Ovarian neoplasma

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ADVANCED CANCER; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CANCER GRADING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHI SQUARE TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; ILIAC ARTERY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OPERATION DURATION; OVARY CARCINOMA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 8844266000     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chambers JT, Chambers SK, Voynick IM, et al. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990;37:327-331.
2. Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150.
3. Schwartz PE, Chambers JT, Makuch R, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994;53:33-37.
4. Vergote I, de Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-436.
5. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-99.
6. Surwit E, Childers J, Atlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-361.
7. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001;91:2319-2334.
8. Lawton FG, Redman CW, Luesley DM, et al. Neoadjuvant (cytoreduction) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-65.
9. Shimizu Y, Hasumi K. Treatment of stage III and IV ovarian cancer: is neoadjuvant chemotherapy effective? Nippon Sanka Fujinka Gakkai Zasshi 1993;45:1007-1014.
10. Kayikcioglu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-470.
11. Chan YM, Ng TY, Ngan HY, et al. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
12. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113-117.
13. Le T, Krepart GV, Lotocki RJ, et al. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67:208-214.
14. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55(3 Pt 2):S91-S96.
15. Hoskins T, McGuire WJ, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974-980.
16. Huober J, Meyer A, Wagner U, et al. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002; 128:153-160.
17. Farias-Eisner R, Teng F, Oliviera M, et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994; 55:108-110.
18. Potter ME, Partridge EE, Hatch KD, et al. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991;40:195-200.